RDC Clinical Pty Ltd

DelveInsight's report on Iron Deficiency Anemia covers epidemiology, market trends in the US, EU4, UK, and Japan. Key trials include Dr. P. Noordzij's study on postoperative iron deficiency anemia treatment and RDC Clinical Pty Ltd's trial on IHAT. The US had 9.5 million prevalent cases in 2023, with females accounting for 65% of cases. Leading companies and therapies are highlighted, including MegaPro Biomedical's MPB-1514 and Pharmacosmos A/S's Ferric Derisomaltose. The report also discusses treatment strategies and market dynamics.